Published October 26, 2020
Follow our Medicare Coronavirus News page for related information on coronavirus (COVID-19) and its impact on Medicare beneficiaries.
Remdesivir, an antiviral drug used to treat COVID-19, was granted approval by the Food and Drug Administration on October 22.
Join our email series to receive your free Medicare guide and the latest information about Medicare and Medicare Advantage.
By clicking "Sign me up!” you are agreeing to receive emails from MedicareAdvantage.com.
Speak with a licensed insurance agent
The drug was given emergency use authorization by the FDA in May, which allowed hospitals and doctors to administer the drug to COVID-19 patients despite not being FDA approved. Remdesivir is now the only FDA-approved drug for the treatment of COVID-19, which had killed more than one million people around the world including some 220,000 Americans before Oct. 22.
The FDA approval comes with the caveat that patients must be at least 12 years of age, weigh at least 88 pounds and require hospitalization for COVID-19.
The intravenous drug is developed by drug maker Gilead and goes by the brand name Veklury.
Numerous studies have shown remdesivir to shorten the recovery time of some COVID-19 patients, though the World Health Organization concluded that the drug has little to no effect on a patient’s survival and is not a cure for the coronavirus.
President Donald Trump was given remdesivir as part of his COVID-19 treatment in early October.
Remdesivir can only be administered by a doctor to a hospital inpatient. As such, it is covered by Medicare Part A and included in the cost of the hospital stay. Medicare Part A beneficiaries are responsible for a hospital deductible of $1,408 per benefit period in 2020.
Medicare’s hospital reimbursement for remdesivir is $2,340 for a five-day course, compared to reimbursement of $3,120 for private insurance for a five-day course. Many health insurance companies waived patient cost-sharing requirements for the drug.
Remdesivir was found in clinical trials to reduce the length of hospital stays from 15 days for patients who received a placebo to 10 days for those who were given remdesivir, and symptoms lingered longer in the patients who did not receive the drug.
Possible side effects of remdesivir include increased levels of liver enzymes, allergic reactions, low blood oxygen level, fever, shortness of breath, wheezing, swelling, rash, nausea, sweating and shivering.
Christian Worstell is a licensed insurance agent and a Senior Staff Writer for MedicareAdvantage.com. He is passionate about helping people navigate the complexities of Medicare and understand their coverage options.
His work has been featured in outlets such as Vox, MSN, and The Washington Post, and he is a frequent contributor to health care and finance blogs.
Christian is a graduate of Shippensburg University with a bachelor’s degree in journalism. He currently lives in Raleigh, NC.
Where you've seen coverage of Christian's research and reports: